Business
Illumina and SPT Labtech unveil fireflyGO, enabling faster, simpler targeted oncology research
Illumina, Inc. (NASDAQ: ILMN) and SPT Labtech today introduced the fireflyGO automation platform, a new benchtop liquid handling and library preparation solution that brings automation, speed, and simplicity to targeted oncology research. Integrated with the MiSeq™ i100 Series, fireflyGO helps laboratories streamline workflows, expand application flexibility, and unlock genomic insights with greater efficiency. By making next-generation sequencing (NGS) more accessible, scalable, and easier to a
About this update from Illumina, Inc.
Automating library prep reduces hands-on time for customers using Pillar Biosciences oncoReveal® targeted oncology research panels SAN DIEGO, May 28, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) and SPT Labtech today introduced the fireflyGO automation platform, a new benchtop liquid handling and library preparation solution that brings automation, speed, and simplicity to targeted oncology research. Integrated with the MiSeq™ i100 Series, fireflyGO helps laboratories streamline workflows, expand application flexibility, and unlock genomic insights with greater efficiency. By making next-generation sequencing (NGS) more accessible, scalable, and easier to adopt, Illumina continues to accelerate the shift toward genomics in cancer testing and as a standard of care in oncology. "Illumina is delivering end-to-end workflow solutions that help customers across the healthcare and research ecosystem make genomic testing more efficient and accessible," said Sandy Ottensmann, vice president and general manager of Global Clinical Solutions. "The fireflyGO platform paired with Illumina MiSeq i100 sequencers and Pillar Biosciences targeted panel assays advances research and serves as a catalyst for broadening genomic testing in cancer, driving shorter turnaround times leading to fast results." Simplified automation for targeted oncology workflows The fireflyGO platform automates library preparation and liquid handling as part of a streamlined workflow for sequencing and analysis on the MiSeq i100 Series. The workflow reduces manual touchpoints, providing higher reproducibility and reliability while reducing laboratory staffing needs. This solution also enables automation capabilities for a growing menu of NGS panels developed by Pillar Biosciences, supporting Illumina's targeted oncology research portfolio. "Simplifying oncology workflows improves research and access to testing with the goal of delivering treatment faster. Our collaboration with Illumina reflects a shared focus on enabling efficient and accessible genomics workflows," said Rob Walton, chief executive officer at SPT Labtech. "By combining SPT Labtech's expertise in automation with Illumina's global strength in sequencing, we are positioned to help labs adopt genomics workflows." Expanding Illumina's oncology research portfolio Illumina is a...